Ionis Receives FDA Approval for TRYNGOLZA (Olezarsen) for Adults with FCS

On December 19, 2024, Ionis Pharmaceuticals, Inc. received FDA approval for TRYNGOLZA (Olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).